Key vendors are focusing on regenerative therapies to increase their sales strategically
Technavio, a company that develops over 2000 pieces of research every year and covers more than 500 technologies across 80 countries, has announced the top five leading vendors for the global CNS disorders therapeutics market in their latest research report. This report also lists various other prominent vendors who are expected to contribute to this market’s growth between 2016-2020.
To identify the top vendors, Technavio’s market research analysts have taken into account the revenue generated by the sales of new drugs along with the decline in revenues due to the patent expiries for the already marketed drugs.
- Depression drugs market: This disease is characterized by loss of interest or pleasure, sadness, feelings of guilt or low self-worth, feelings of tiredness, disturbed sleep or appetite, and poor concentration.
- MS drugs market: This medical condition results in demyelination, axonal transection, and neurodegeneration of the nerve cells in the brain and spinal cord.
This Technavio report, under central nervous system vertical, is based on the synthesis, analysis, and interpretation of information about the global CNS disorders therapeutics market collected from specialized sources. The analysts have derived insights using a mix of primary and secondary research with an aim to provide a holistic picture of the market.
Click here to request a free sample of this report
Competitive vendor landscape
The players in the global CNS disorders therapeutics market are undertaking strategic initiatives to drive growth and profitability. The competition in the market is maintained by the established vendors. Many companies are forming partnerships to develop new drugs to treat various diseases and to sustain the competition in the market. The manufacturers are replacing first-generation drugs with new and improved formulation of second-generation drugs. The companies are investing in direct-to-consumer advertising to attract more customers and maintain the market share. Several sellers are developing a drug discovery platform to create individualized and a new treatment method. Companies are focusing on marketing their CNS disorder treatment drugs in the US and worldwide through regulatory approvals to increase their global footprint.
“The vendors are focusing on the development of regenerative medicine for the treatment of CNS disorders. These regenerative therapies help in the healing process by replacement or regeneration of the human cells, tissues, and organs. Some of these regenerative therapies include stem cells, growth factors, and the use of matrices, like fibrin, collagen, and hyaluronic acid. Companies are investing in innovative technologies to develop better regenerative medicines,” says Barath Palada, a lead analyst at Technavio for research on central nervous system.
Top five vendors in the CNS disorders therapeutics market space
GlaxoSmithKline
GlaxoSmithKline manufactures and markets pharmaceutical products which include over-the-counter (OTC) products, vaccines, and health-related consumer products across the world. Recently, the company released the 24-month clinical study to evaluate the effect of rilapladib on cognition and cerebrospinal fluid biomarkers of AD.
Some key products: Imigran/Imitrex, Lamictal, Lamictal XR (extended-release), Potiga (US)/Trobalt (EU), etc.
Pfizer
The company produces, manufactures, and develops a wide range of pharmaceutical products for various therapy areas including arthritis, cardiovascular, metabolic disorders, infectious, and respiratory. In recent times, the company collaborated with GlaxoSmithKline to invest $100 million funds in exploring new approaches to AD.
Some key products: Alsuma, Celontin, Cerebyx, Dilantin-125, etc.
Eli Lilly
Eli lily develops drugs for the treatment of diseases in various therapeutic areas such as oncology, neuroscience, endocrinology, cardiovascular, and animal health. The company also focuses on research on diabetes, oncology, and neurodegeneration. Recently, the company announced that its investigational medicine for prevention of a migraine (LY2951742) met the primary endpoint in a Phase IIb study in an episodic migraine.
Some key products: Cymbalta, Prozac, Strattera, Symbyax, etc.
Janssen Pharmaceuticals
The company focuses on the development of drugs for mental health diseases like schizophrenia, bipolar disorder, and other neurologic conditions, ADHD, women’s health, and pain management. In recent times, the company announced the submission of a supplemental NDA to the US FDA, seeking a label change for its Invega Sustenna drug.
Some key products: Concerta, Invega Sustenna, Razadyne ER/Reminyl ER, Razadyne/Reminyl, etc.
Novartis
Novartis engages in the R&D, manufacturing, and marketing of a wide range of pharmaceuticals for the treatment of various diseases including CNS disorders such as bipolar disorder, depression, epilepsy, migraine, AD, Huntington’s disease (HD), and MS. Recently, the company announced a partnership with Amgen to develop and market neuroscience treatment options.
Some key products: Comtan, Exelon patch, Extavia, Gilenya, etc.
Other prominent vendors in this market include AB Science, AbbVie, Abital Pharma, Acorda Therapeutics, Active Biotech, Adamas Pharmaceuticals, Addex Therapeutics, Akorn, Alcobra, Alexza Pharmaceuticals, Alkermes, Amarantus, Aprecia Pharmaceuticals, Archer Pharmaceuticals, Astellas, AstraZeneca, Aurobindo Pharma, Auspex Pharmaceuticals, Avanir Pharmaceuticals, Biscayne Pharmaceuticals, Boehringer Ingelheim, Cerecor, Chugai Pharmaceutical, Concordia, Convergence Pharmaceuticals, Curemark, CURx Pharmaceuticals, Dainippon Sumitomo Pharma, Dart NeuroScience, Delpor, Desitin Arzneimittel, D-Pharm, Dr. Reddy’s Laboratories, Edgemont Pharmaceuticals, Endo International, E-Therapeutics, Euthymics, Evotec, F. Hoffmann-La Roche, Fabre-Kramer, Forum Pharmaceuticals, Gedeon Richter, Glenmark, Grupo Ferrer Internacional, GW Pharmaceuticals, GW Pharmaceuticals, Hisamitsu, Impax, Insero Health, INSYS Therapeutics, Intellipharmaceutics, Intra-Cellular Therapies, Intra-Cellular Therapies, Kyowa Hakko Kirin, Ipsen, Ligand Pharmaceuticals, Lundbeck, Lupin, Luye Pharma, MarcoPolo Pharmaceuticals, Marinus Pharmaceuticals, Meda AB, Merck, Mitsubishi Tanabe, MorphoSys AG, MSI Methylation Sciences, Mylan, Naurex, Neuralstem, Neurelis, Neurovance, Nobelpharma, Noven Pharmaceuticals, Omeros Corporation, Opexa, Opko Health, Orion, Ophelia Pharmaceutical, Otsuka Pharmaceuticals, Palobiofarma, Par Pharmaceuticals, Pierre Fabre, PNBDevCo, Prana Biotechnology, Raptor Pharmaceutical, Reviva Pharmaceuticals, Reviva Pharmaceuticals , Sanofi, SciFlour, Sedor Pharmaceuticals, Shire, Siena Biotech, SK Biopharmaceuticals, SOM Biotech, Somerset Pharmaceuticals, STADA Arzneimittel, Sun Pharmaceutical, Sunovion Pharmaceuticals (US), Supernus Pharmaceuticals, Suven, Takeda Pharmaceuticals, Teva Pharmaceuticals, Torrent Pharmaceuticals, Tris Pharma, Turing Pharmaceuticals, UCB, US WorldMeds, Valeant Pharmaceuticals, Zinfandel Pharmaceuticals, and Zogenix.
A more detailed analysis is available in the Technavio report, Global CNS Disorders Therapeutics Market 2016-2020. Technavio also customizes reports by other regions and specific segments upon request.
To read more press releases- click here.
Browse related reports:
- Global Generic Drugs Market 2016-2020
- Global Transcriptomics Market 2016-2020
- Global Insomnia Market – Market Research Analysis 2015-2019
For any assistance or query, please contact our media team at:
media@technavio.com
US: +1 630 333 9501
UK: +44 208 123 1770
www.technavio.com
